Prosecution Insights
Last updated: November 04, 2026
Application No. 18/434,663

PHARMACEUTICAL COMPOSITION AND METHOD FOR INHIBITING ANGIOGENESIS

Final Rejection §102
Filed
Feb 06, 2024
Priority
Mar 20, 2023 — provisional 63/453,225
Examiner
KATAKAM, SUDHAKAR
Art Unit
1658
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Zih Yuan Tang Biotechnology Co. Ltd.
OA Round
2 (Final)
75%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
98%
With Interview

Examiner Intelligence

Grants 75% — above average
75%
Career Allowance Rate
977 granted / 1307 resolved
+14.8% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 6m
Avg Prosecution
83 currently pending
Career history
1385
Total Applications
across all art units

Statute-Specific Performance

§101
1.7%
-38.3% vs TC avg
§103
44.6%
+4.6% vs TC avg
§102
13.0%
-27.0% vs TC avg
§112
25.4%
-14.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1307 resolved cases

Office Action

§102
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Status of the application Receipt of applicant’s remarks and claim amendments filed on 08/13/2026 are acknowledged. In light of claim amendments previous Claim Objections is withdrawn. In light of cancellation of claims 3-4 previous 112(b) is withdrawn. In light of cancellation of claims 5-8 previous 101 rejection is withdrawn. In light of cancellation of claims 3-8 previous 102 rejections for these claims are withdrawn. However, applicants’ arguments for the previous 102 rejection for claims 1-2 are found not persuasive. Accordingly, the previous rejection is maintained. Please see the examiners response to applicants arguments below. Response to Arguments Applicants’ main argument is that Lee discloses only body-weight doses administered systemically, specifically beauvericin administered intraperitoneally at 2.4 mg/kg or orally at 24 mg/kg in mice. Lee never discloses any concentration of beauvericin in a composition, let alone the recited concentration of 0.5 mM to 5 mM. The Examiner's asserted equivalence of 0.1 mM to approximately 0.078 mg/kg and 5 mM to approximately 3.92 mg/kg rests on a units mismatch. A micromolar concentration of beauvericin (molecular weight 783.96) corresponds to milligrams per liter of solution, not milligrams per kilogram of body weight. Converting a systemic body-weight dose into a local concentration would require pharmacokinetic distribution data that Lee does not provide. Accordingly, the record does not support the conversion the Examiner has made, and it cannot support a finding of anticipation. The calculation is made with the following equation: The general formula to convert a micromolar concentration to mg/kg is:mg/kg = (µM × Molecular Weight in g/mol) ÷ 1000Where: µM = micromoles per liter (or per kg of solution) Molecular Weight (MW) = molecular weight of the compound in g/mol 1000 = conversion factor from micrograms to milligrams Step-by-Step Example Suppose you have a compound with a molecular weight of 783.9 g/mol and a concentration of 5 µM: Multiply the micromolar concentration by the molecular weight:5 µM × 783.9 g/mol = 3,919 µg/L Convert micrograms to milligrams:3,919 µg ÷ 1000 = 3.919 mg/L (or mg/kg if solution density ≈ 1 kg/L)So, 5 µM corresponds to 3.92 mg/kg for this compound. Claims simply require concentration and do not require body weight etc. Applicants further argue that the specification as filed discloses that it was unexpectedly discovered that "beauvericin at a low concentration provides an efficacy in inhibition of angiogenesis". Applicants claimed concentration range matched with the concentration disclosed in disclosure of Lee. Since it is identical, the so called unexpected results are not unexpected. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1-2 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Lee (US20200316165A1). For claims 1-2: Lee discloses treating angiogenesis by administering 2.4 mg/kg of beauvericin [see Fig.1-2; 0015, 0023, 0025, 0032 and 0036], wherein 2.4 mg/kg falls within applicants claimed range 0.1 mM (~0.078 mg/kg) to 5 mM (~3.92 mg/kg). Accordingly, the claims are fully anticipated. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUDHAKAR KATAKAM whose telephone number is (571)272-9929. The examiner can normally be reached 8:30 am to 5 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melissa Fisher can be reached at 571-270-7430. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUDHAKAR KATAKAM/Primary Examiner, Art Unit 1658
Read full office action

Prosecution Timeline

Feb 06, 2024
Application Filed
Mar 14, 2024
Response after Non-Final Action
May 14, 2026
Non-Final Rejection mailed — §102
Aug 13, 2026
Response Filed
Oct 22, 2026
Final Rejection mailed — §102 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780875
POLYPEPTIDES INCLUDING A BETA-TRICALCIUM PHOSPHATE-BINDING SEQUENCE AND USES THEREOF
3y 2m to grant Granted Nov 03, 2026
Patent 12780876
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 1m to grant Granted Nov 03, 2026
Patent 12766196
PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS
3y 6m to grant Granted Oct 20, 2026
Patent 12760066
BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS
5y 0m to grant Granted Oct 13, 2026
Patent 12760070
CYCLIC CELL PENETRATING PEPTIDES AND METHODS OF MAKING AND USING THEREOF
1y 0m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
75%
Grant Probability
98%
With Interview (+23.3%)
2y 6m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 1307 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month